Oxurion NV.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Heverlee Belgium (1991)

Organization Overview

First Clinical Trial
2004
NCT00123279
First Marketed Drug
2012
ocriplasmin (jetrea)
First NDA Approval
2012
ocriplasmin (jetrea)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Oxurion | Oxurion NV. | Thrombogenics | ThromboGenics | ThromboGenics Inc. | THROMBOGENICS, INC | ThromboGenics Inc. A subsidiary of Oxurion NV. | Thrombogenics NV

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 2)

Diabetic Retinopathy (Phase 2)

Disease Progression (Phase 2)

Edema (Phase 2)

Eye Diseases (Phase 2)

Macular Degeneration (Phase 2)

Macular Edema (Phase 2)

Neoplasms (Phase 1)

Retinal Diseases (Phase 2)

Retinal Perforations (Phase 3)

Retinal Telangiectasis (Phase 2)

Stroke (Phase 2)

Telangiectasis (Phase 2)

Thromboembolism (Phase 2)

Thrombosis (Phase 2)

Tissue Adhesions (Phase 3)

Venous Thrombosis (Phase 2)

Vitreous Detachment (Phase 2)

Wet Macular Degeneration (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 31
  • # of Trial APIs: 13